|
T25196 |
BZAD01
|
BZAD-01,BZAD 01 |
NMDAR
|
|
BZAD01 is a selective NMDA NR1A/2B receptor antagonist. |
|
T22674 |
Co 101244 hydrochloride
|
4-Piperidinol, 1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-Methylphenyl)Methyl]-,hydrochloride |
NMDAR
|
|
Co 101244 hydrochloride (4-Piperidinol, 1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-Methylphenyl)Methyl]-,hydrochloride) is an NR2B-containing NMDA receptor antagonist. |
|
T13112L1 |
Tat-NR2B9c acetate
|
Tat-NR2B9c acetate (500992-11-0 Free base),NA-1 acetate |
Others
|
|
Tat-NR2B9c acetate (NA-1 acetate) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c acetate disrupts the PSD-... |
|
T13112 |
Tat-NR2B9c
|
Tat-NR2Bct,NA-1 |
NO Synthase
,
iGluR
|
|
Tat-NR2B9c (NA-1) is a postsynaptic density-95 (PSD-95) inhibitor with neuroprotective and antiepileptic effects.Tat-NR2B9c inhibits PSD-95d2, PSD-95d1, and PSD-95, which prevents the activation of NMDA-induced NADPH oxi... |
|
T81037 |
Tat-HA-NR2B9c
|
|
|
|
Tat-HA-NR2B9, comprising an HIV-1 Tat transduction domain fragment, an influenza virus hemagglutinin (HA) epitope-tag, and the C-terminal 9 amino acids of NR2B (NR2B9c), has demonstrated efficacy in reducing infarct size... |
|
T35924 |
Tat-NR2Baa
|
Tat-NR2Baa |
|
|
Tat-NR2BAA is an inactive control peptide of Tat-NR2B9c. It shares a similar sequence with Tat-NR2B9c, but possesses a double-point mutation in the COOH terminal tSXV motif. This mutation renders Tat-NR2BAA unable to bin... |
|
T76069 |
Tat-NR2Baa TFA
|
|
|
|
Tat-NR2BAA TFA serves as the inactive control peptide for Tat-NR2B9c, featuring a comparable sequence with a crucial distinction: a double-point mutation in its COOH-terminal tSXV motif. This alteration renders Tat-NR2BA... |
|
T13112L |
Tat-NR2B9c TFA
|
NA-1 (TFA) |
Others
|
|
Tat-NR2B9c TFA is a 20-aa peptide, and acts as an inhibitor of postsynaptic density-95 (PSD-95)(EC50 of 6.7 nM for PSD-95d2), and possesses neuroprotective efficacy. |
|
T1751 |
Eliprodil
|
SL-820715 |
NMDAR
,
iGluR
|
|
Eliprodil (SL-820715)(SL-820715), a non-competitive NR2B-NMDA receptor antagonist(IC50: 1 uM), less effective for NR2A- and NR2C-containing receptors(IC50> 100 uM). It has been used in trials studying the treatment of Pa... |
|
T5385 |
Radiprodil
|
RGH-896 |
NMDAR
,
iGluR
|
|
Radiprodil (RGH-896) (RGH-896) is an orally active and selective NMDA NR2B receptors antagonist. It was a potential treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP). |
|
T12234 |
NMDA-IN-1
|
|
NMDAR
|
|
NMDA-IN-1 is a potent and NR2B-selective antagonist of NMDA(NMDA Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM). |
|
T12758 |
Ro 25-6981
|
|
NMDAR
|
|
|
|
T23449 |
TCS 46b
|
|
NMDAR
|
|
NR1A/NR2B NMDA receptor antagonist,orally active |
|
T8920 |
Sepimostat
|
|
iGluR
|
|
Sepimostat exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat dimethanesulfonate inhibits the Ifenprodil binding with a Ki v... |
|
T5522 |
NMDAR antagonist 1
|
|
Others
,
iGluR
|
|
NMDAR antagonist 1 is an orally active, NR2B-selective NMDAR antagonist. |
|
T8450 |
TCN 213
|
TCN213 |
NMDAR
|
|
TCN 213 is an antagonist of NMDA receptor that has a selective for NR1/NR2A over NR1/NR2B |
|
T23457 |
Threo Ifenprodil hemitartrate
|
|
Others
|
|
σ receptor agonist and NR2B subunit-selective NMDA receptor antagonist |
|
T12758L |
Ro 25-6981 Maleate
|
|
Others
|
|
Ro 25-6981 Maleate is a potent and selective activity-dependent NMDA receptors blocker containing the NR2B subunit.(IC50 values are 0.009 and 52 μM for cloned receptor subunit combinations NR1C/NR2B and NR1C/NR2A respect... |
|
T40999 |
NMDA receptor antagonist 2
|
|
|
|
NMDA receptor antagonist 2 is a highly potent and orally active NR2B subtype-selective antagonist of the N-methyl-D-aspartate (NMDA) receptor. It exhibits remarkable binding affinities, with an IC50 of 1.0 nM and a Ki va... |
|
T23239 |
Ro 04-5595 hydrochloride
|
|
Others
|
|
NR2B-containing NMDA receptors antagonist |
|
TP2060 |
Conantokin G
|
|
|
|
GluN2B (formally NR2B) selective, competitive antagonist of the NMDA receptor. Blocks NMDA-evoked current in mouse cortical neurons (IC50 = 480 nM); also inhibits NMDA-evoked responses in oocytes expressing GluN2B (forma... |
|
T31046 |
CP-283097
|
CP283097,UNII-WHL1Z3GN15,CP 283097 |
|
|
CP-283097 is an N-methyl-D-aspartic acid (NMDA) receptor antagonist with NR2B subunit. |
|
T70055 |
CO-101244 Free Base
|
|
|
|
CO-101244 Free Base is an NMDA receptor NR2B subunit blocker. |
|
T37096 |
Sepimostat dimethanesulfonate
|
|
|
|
Sepimostat dimethanesulfonate (FUT-187), a chemical compound, demonstrates neuroprotective properties by antagonizing NR2B N-methyl-D-aspartate receptors at the NR2B subunit's Ifenprodil-binding site. This compound effec... |
|
T30428 |
Besonprodil
|
Besonprodil (USAN),UNII-5K3N2D15WW,253450-09-8,CHEMBL219631,CI-1041 |
|
|
Besonprodil is a drug that acts as an NMDA antagonist and is selective for the NR2B subunit. |
|
T24717 |
Ro 25-6981 HCl
|
Ro 25 6981 HCl |
|
|
Ro 25-6981 HCl is an effective and selective NMDA glutamate receptors containing the NR2B subunit antagonist. |
|
T23809 |
BMT-108908
|
BMT108908 |
|
|
BMT-108908 is a Negative Allosteric Modulator. It is selective for the NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains. |
|
T70049 |
Ro 04-5595 free base
|
|
|
|
Ro 04-5595 is a selective antagonist of NMDA receptors NR2B subunits. Ro 04-5595 had an EC 50 of 186 ± 32 nmol/L. Ro 04-5595 was predicted to bind the EVT-101 binding site, not the ifenprodil-binding site. Specific bindi... |
|
TQ0233L |
Traxoprodil Mesylate
|
|
|
|
Traxoprodil Mesylate is a potent noncompetitive N-methyl-D-aspartate (NMDA) receptors antagonist and has selective for the NR2B subunit. |
|
T68255 |
CJ 036878
|
|
|
|
CJ 036878 was developed as an antagonist of the N-methyl-D-aspartate receptor NR2B subunit. |
|
T68973 |
EVT-101 free base
|
|
|
|
EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder. It acts as a selective NMDA receptor subunit... |
|
T62126 |
(Rac)-NMDAR antagonist 1
|
|
|
|
(Rac)-NMDAR antagonist 1 is a racemate of NMDAR antagonist 1. NMDAR antagonist 1 is a potent, orally active, NR2B-selective NMDAR antagonist. |
|
T61319 |
Onfasprodil
|
|
|
|
Onfasprodil, a negative allosteric modulator of NR2B, has been identified as a potential compound for researching Alzheimer's disease. This compound, in combination with a GABA receptor regulator.[1] |
|
T41058 |
Nelonemdaz potassium
|
Neu2000potassium,Salfaprodil |
|
|
Nelonemdaz potassium (also known as Salfaprodil) is a potent NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). This compound exhibits remarkable neuroprotection against cell death induced by bot... |
|
T83731 |
Tat-CBD3 TFA
|
|
|
|
Tat-CBD3 is a chemical compound inhibiting the interaction between the N-type voltage-gated calcium channel Cav2.2 and collapsin response mediator protein 2 (CRMP2), as well as the interaction between CRMP2 and the NMDA ... |
|
T37671 |
CAY10608
|
CAY10608 |
|
|
N-Methyl-D-aspartate (NMDA) receptors are Ca2+ permeable ligand-gated channels of the central nervous system that are activated after binding of the co-agonists glutamate and glycine. CAY10608 is a propanolamine that pot... |
|
T37215 |
5α,6β-Dihydroxycholestanol
|
|
|
|
5α,6β-Dihydroxycholestanol is an oxysterol metabolite of cholesterol formed from conversion of cholesterol epoxides by 5,6-epoxysterol hydrolase. It inhibits NMDA-mediated calcium influx in HEK293 cells expressing NR1/NR... |
